Multimedia Appendix 3

Results of included studies (Table 3) and Risk of bias assessment (Table 4)

 Table 3. Results of included studies

Study	Attrition rate	Adherence sessions completion	Adherence rate practice frequency	Adherence rate practice time	Outcomes ^a	Postintervo Cohen's d	ention ^b	Follow-up ^c Cohen's d	
						Within- subject	Between- group	Within- subject	Between- group
Atreya et al.	32%	N/A	N/A	N/A		8 weeks ^d			
(2018) [75]					Distress (thermometer)	-0.17	_	_	_
					anxiety (PROMIS)	-0.10	_	_	_
					depression (PROMIS)	0.07	_	_	_
					fatigue (PROMIS)	-0.42	_	_	_
					sleep disturbances (PROMIS)	-0.19	_	_	_
					global mental health (PROMIS)	0.11	_	_	_
					global physical health (PROMIS)	N/A	_	_	_
					acting with awareness (FFMQ)	-0.31	_	_	_
					describing (FFMQ)	0.13	_	_	_
					nonjudging (FFMQ)	-0.27	_	_	_
					nonreactivity (FFMQ)	0.31	_	_	_
					observing (FFMQ)	0.20	_	_	_
Brotto et al.	46%	43% of enrolled participants	N/A	N/A		12 weeks		6 months	
(2017) [76]		completed full intervention			Sex-related distress F (FSDS)	-0.47	_	-0.57	_
		_			sex-related distress Ma (FSDS)	0.26	_	0.01	_
					Sexual functioning F (FSFI)	1.04	_	N/A	_
					Sexual functioning Ma (IIEF)	0.28	_	N/A	_
					depression F (BDI)	-0.38	_	N/A	_
					depression Ma (BDI)	0.20	_	N/A	_
Bruggeman-	27%	62% of enrolled participants	N/A	N/A					6 months
Everts et al.	27,70	attended two thirds or more	1 1/1 2	1 1/11	Fatigue severity (CIS-FS)	_	_	_	-0.69
(2017) [84]		sessions			positive affects (PANAS)	_	_	_	0.04
(/ L - 1					negative affects (PANAS)	_	_		-0.07
					anxiety and depression (HADS)	_	_	_	-0.04
Dengaaman	38%	620% of annulled participants	N/A	N/A				13 weeks	
Bruggeman- Everts et al.	36%	62% of enrolled participants completed at least two thirds	1 N / <i>I</i> A	1 N / <i>P</i> A	Fatigue severity (CIS-FS)			-1.45	
(2015) [77]		or more of intervention			anxiety and depression (HADS)	_	_	-1.45 -0.71	
(2013)[//]		of more of intervention			anxiety and depression (HADS)	_	_	-0.71	_

Study	Attrition rate	Adherence sessions completion	Adherence rate practice frequency	Adherence rate practice time	Outcomes ^a	Postinterve Cohen's d	ention ^b	Follow-up ^c Cohen's d	
						Within- subject	Between- group	Within- subject	Between- group
Campo et al. (2017) [78]	29%	84%° attended at least 6 out of 8 sessions	Unclear e f g; M of formal practice was 3.11 days/week (SD = 1.61); data of 46% enrolled participants N/A	Unclear e f g; M = 33.45min/week (SD = 16.59) (= 4.8min/day)	Anxiety (PROMIS) depression (PROMIS) social isolation (PROMIS) mindfulness (MAAS) posttraumatic growth (PTGI) body image (BIS) resilience (BRS) self-compassion (SCS)	8weeks -1.24*** -0.99*** -1.10*** 0.87*** 0.50** -1.39*** 0.33			
Compen et al. (2018) [62]; Cillessen et al. (2018) [70]; Bisseling et al. (2019) [73]	30%	79% of enrolled participants attended half or more sessions	N/A	Uncleare; M = 28.7min/day (SD = 29.3min) (R = 30min/day); data of 23% enrolled participants N/A	Anxiety and depression (HADS) fear of recurrence (FCRI) rumination (RRQ) QoL-mental (SF-12) QoL-physical (SF-12) mindfulness (FFMQ-SF) positive mental health (MHC-SF)		8weeks -0.71 -0.53 -0.51 0.67 0.24 0.82 0.44	9 months ^{f g} -0.32 -0.10 -0.28 0.39 0.00 N/A 0.48	
Donovan et al. (2019) [79]	6%	On average, completers completed a mean 16.9 (SD 11.9, range 0-28) of the 28 unique sessions	N/A	N/A	Social support (PSS-Fr) mindfulness (CAMM) psychological functioning (PCQL) body image distress (BIS)	4 weeks -0.22 -0.18 0.14 -0.31	_ _ _ _		
Hawkes et al. (2014) [71]; Hawkes et al. (2013) [74]	23%	81% ^{fh} attended half or more of sessions	N/A	N/A	Mindfulness (MAAS) quality of life (FACT-C) QoL-physical (SF-36) QoL-mental (SF-36) distress (BSI-18) posttraumatic growth (PTGI) spirituality (FACIT-sp) acceptance (AAQ-II) cancer fatigue (FACIT-FS)		6 months 0.00 0.12 0.00 0.07 0.01 0.32 0.36 0.47		12 months 0.00 0.10 0.13 -0.08 -0.04 0.21 0.13 -0.01 0.07
Huberty et al. (2019) [85]; Puzia et al. (2020) [72]	27%		N/A	56% of completers was adherent to at least 70%; M = 56% practiced at least 49min/week R = 10min/day data of 27% enrollers are N/A	Pain intensity (PROMIS) anxiety (PROMIS) depression (PROMIS) sleep disturbance (PROMIS) satisfaction w/ sex life physical health (PROMIS) mental health (PROMIS) total symptom burden (MPN-SAF) fatigue (MPN-SAF)	4 weeks ⁱ -0.11 -0.22 -0.29 -0.47 -0.22 0.44 -0.25 -0.27	4 weeks ⁱ -0.10 -0.70 ^j -0.04 ^j -0.42 ^j -0.21 -0.31 -0.26 -0.29 -0.31		

oers))17)	Within-subject With	Between- group 9 months 0.19 -0.09 0.14 -0.12 0.15 0.11 0.07 0.16 0.16 0.03
	N/A Psychological distress (BSI-18)	9 months 0.19 -0.09 0.14 -0.12 0.15 0.11 0.07 0.16
	Psychological distress (BSI-18) — — — cancer-specific distress (IES) — — — anxiety (MAX-PC) — — — quality of life (FACT-p) — — — benefit finding (PTGI) — — — observing (FFMQ) — — — describing (FFMQ) — — — acting with awareness (FFMQ) — — — nonjudging (FFMQ) — — —	0.19 -0.09 0.14 -0.12 0.15 0.11 0.07 0.16
, 1 , ,	cancer-specific distress (IES) — — — anxiety (MAX-PC) — — — quality of life (FACT-p) — — — benefit finding (PTGI) — — — observing (FFMQ) — — — describing (FFMQ) — — — acting with awareness (FFMQ) — — — nonjudging (FFMQ) — — —	-0.09 0.14 -0.12 0.15 0.11 0.07 0.16 0.16
	anxiety (MAX-PC) — — — quality of life (FACT-p) — — — benefit finding (PTGI) — — — observing (FFMQ) — — — describing (FFMQ) — — — acting with awareness (FFMQ) — — — nonjudging (FFMQ) — — —	0.14 -0.12 0.15 0.11 0.07 0.16 0.16
	quality of life (FACT-p) — — benefit finding (PTGI) — — observing (FFMQ) — — describing (FFMQ) — — acting with awareness (FFMQ) — — nonjudging (FFMQ) — —	-0.12 0.15 0.11 0.07 0.16 0.16
	benefit finding (PTGI) — — — — — — — — — — — — — — — — — — —	0.15 0.11 0.07 0.16 0.16
	observing (FFMQ) — — — describing (FFMQ) — — — acting with awareness (FFMQ) — — — nonjudging (FFMQ) — — —	0.11 0.07 0.16 0.16
	describing (FFMQ) — — — — acting with awareness (FFMQ) — — — — nonjudging (FFMQ) — — — — —	0.07 0.16 0.16
	acting with awareness (FFMQ) — — — — nonjudging (FFMQ) — — — — —	0.16
	nonreactivity (FFMO) — — —	0.03
et	Inclear ^k ; N/A 10 weeks	
[80	verage of completers was 2.8 Quality of life (FACT-O) 0.29 — —	_
	imes per week (range 0.22- perceived stress (PSS) -0.43 — —	_
	.33). Data of 32% enrolled mood disturbances (POMS) -0.28 — —	_
	articipants N/A. depression (CESD) -0.28 — —	_
	sleep problems (PSQI) -0.10 — —	_
	social support (SPS) 0.12 — —	_
et a	0% of completers were N/A 8 weeks 8 weeks	
[87		_
		_
		_
		_
		_
		_
		_
		_
		_
		_
	Describing (PFMQ-SF) 0.15 0.18 —	_
		_
		_
	Nonreacting (FFMQ-SF) 0.48 0.45 —	_
et a	V/A N/A 8 weeks	
[54	,	_
		_
		_
		_
		_
		_
	sleep problems (PSQI) -0.57 — —	_
et a	ney practiced at least 50% of anxiety (HADS-anx) -0.31 -0.40 ays (recommendation was to depression (HADS-dep) -0.37 0.01 reactice every day). Data of pain intensity (PROMIS) -0.35 -0.47 9 pain interference (PROMIS) -0.31 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -0.30 1 -	0 — — — — — — — — — — — — — — — — — — —

Study	Attrition rate	Adherence sessions completion	Adherence rate practice frequency	Adherence rate practice time	Outcomes ^a	Postinterve Cohen's d	ention ^b	Follow-up ^c Cohen's d	
						Within- subject	Between- group	Within- subject	Between- group
Lengacher et al. (2018) [81]	13%		N/A	67% of completers was adherent to 100%; average of all participants was 36min/day and 67% of them practiced higher than 20min/day as recommended; data of 20% enrolled participants N/A	QoL-physical (SF-36) QoL-mental (SF-36) observing (FFMQ) describing (FFMQ) acting with awareness (FFMQ) nonjudging (FFMQ) mindfulness total (FFMQ) cognitive impairment (EoCG) depression (CESD) anxiety (STAI-S) perceived stress (PSS) fear of recurrence (CARS) sleep problems (PSQI) fatigue symptoms (FSI) fatigue interference (FSI)	6 weeks 0.29 0.11 0.64 0.15 0.53 1.16 0.68 0.83 -0.66 -0.85 -0.72 -0.84 -0.74 -0.34 -0.60 -0.47			group
Messer et al. (2019) [88]	9%	N/A	Unclear*; M = 13 exercises over the course (approx. 2 exercises/week) R: daily data of 9% enrolled participants N/A	N/A	pain severity (BPI) pain interference (BPI) Depression and anxiety (HADS) mood disturbance (POMS) sleep problems (PSQI) fatigue (FSI)	-0.03 -0.16	6 weeks ¹ -0.64 -0.67 -1.14 -1.03		
Mikolasek et al. (2018) [82]	46%		Unclear ^c ; Mdn = 4 (IQR = 1-7; at week 1) and 2 (IQR = 1-4; at week 10) exercises/week of recommended 5 exercises/week; data of 46% enrolled participants N/A	N/A	Distress (thermometer) anxiety and depression (HADS) quality of life (FACT-G) health-related QoL (PROMIS) fear of progression (FOP-Q-SF) mindfulness (FMI)	10 weeks ^m N/A N/A N/A N/A N/A N/A	_ _ _ _	20 weeks ^m N/A N/A N/A N/A N/A N/A	
Milbury et al. (2020) [89]	27%	76% of participants attended more than half of intervention (at least 3 sessions)	N/A	N/A	Depression (CES-D) cancer-related stress (IES) spiritual well-being (FACT-SP)	_ _ _	4 weeks ⁿ N/A N/A N/A	_ _ _	3 months ⁿ -0.53 -0.68 0.26

Study	Attrition rate	Adherence sessions completion	Adherence rate practice frequency	Adherence rate practice time	Outcomes ^a	Postinterve Cohen's d	ention ^b	Follow-up ^c Cohen's d	
						Within- subject	Between- group	Within- subject	Between
Mosher et al.	22%	83% of enrolled participants	N/A	N/A					12 week
(2018) [90]		attended half or more of			Symptom interference (MDASI)	_	_	_	-0.34
		sessions			pain interference (PROMIS)	_	_	_	-0.02
					fatigue interference (FSI)	_	_	_	-0.27
					sleep impairment (PROMIS)	_	_	_	-0.38
					pain intensity (PROMIS)	_	_	_	-0.17
					fatigue (PROMIS)	_	_	_	-0.19
					sleep disturbances (PROMIS)	_	_	_	-0.25
					depressive symptoms (PROMIS)	_	_	_	0.01
					anxiety (PROMIS)	_	_	_	-0.10
Nissen et al.	26%	56% of enrolled participants	N/A	Unclearko;			8 weeks		6 month
(2020) [91]		completed all eight sessions		M = login time was 6 hours	Anxiety (STAI-Y)	_	-0.45	_	-0.40
				and 38 minutes per completed	depression (BDI-II)	_	-0.42	_	-0.28
		all enrolled participants		module	stress (PSS)	_	-0.18	_	-0.29
		completed an average of 5.6			mental well-being (WHO-5)	_	0.20	_	0.43
		sessions out of eight			sleep disturbances (ISI)	_	0.06	_	0.04
Plumb	12%	95% of enrolled participants	N/A	N/A		4 weeks ¹			
Vilardaga et		completed all four sessions			Pain severity (BPI-severity)	-0.09	_	_	_
al. (2020)		completed an four sessions			pain disability (PDI)	-0.15	_	_	_
[83]					fatigue (PROMIS)	-0.08	_	_	_
. ,					anxiety (HADS-anx)	-0.13	_	_	_
					depression (HADS-dep)	-0.17	_	_	_
					acceptance and action (AAQ-II)	-0.12	_	_	_
					values summary (VAL-sum)	-0.17	_	_	_
Price-	26%	77% of completers reported	N/A	N/A		8 weeks ^p			
Blackshear		watching all eight assigned			Anxiety (PROMIS)	-0.59	_	_	_
et al. (2020)		session videos			depression (PROMIS)	-0.39	_	_	_
[92]					stress (PSS)	-0.75	_	_	_
-					fatigue (N/A)	-0.42	_	_	_
					mindfulness (MAAS)	0.23	_	_	_
					dyadic adjustment (DAS)	0.11	_	_	_
					quality of marriage (QMI)	0.14	_	_	_
					interpersonal mindfulness (IMS)	0.39	_	_	_

Study	Attrition rate	Adherence sessions completion	Adherence rate practice frequency	Adherence rate practice time	Outcomes ^a	Postinterve Cohen's d	ention ^b	Follow-up ^c Cohen's d	
						Within- subject	Between- group	Within- subject	Between- group
Rosen et al. (2018) [93]	46%	_	Unclear ^{g k} ; participants logged into the app on average 18 days over the course (range 1-78 days) (= 2.25 day/week); data of 40% started participants N/A	Unclear g k; average duration of app engagement was 13.40 minutes per day (range 10 to 40 minutes). Individual mindfulness sessions ranged 3 to 20 minutes; data of 40% started participants N/A	General well-being (FACT-B) mindfulness (MAAS)	=	9 weeks 0.36 0.38		13 weeks 0.31 0.30
Russell et al. (2019) [94]	30%	N/A	61%-80% of completers were 100% adherent; 61% (at week 2) and 80% (at week 4) practiced every day as recommended; data of 50% (at week 2) and 67% (at week 4) enrolled participants N/A	N/A	Fear of cancer recurrence (FCRI) rumination (RRQ-rum) mindfulness (CAMS-R) worries (PSQW-A) stress (PSS-10)	_ _ _ _	6 weeks -1.42 -1.49 -0.42 -0.34 -0.65	 	
Zernicke et al. (2014) [95]; Zernicke et al. (2016) [97]	18% ⁱ	82% of enrolled participants completed half or more sessions ^g	N/A	Unclear ^{g k} M = 134min/5days week (= 26.8min/day) (R = 45min/day); data of 18% enrolled participants N/A	Mood disturbancess (POMS) stress (CSOSI) spiritual well-being (FACIT-sp) posttraumatic growth (PTGI) observing (FFMQ) describing (FFMQ) acting with awareness (FFMQ) nonjudging (FFMQ) nonreactivity (FFMQ)	8 weeks' -0.61 -0.83 0.60 0.55 0.31 0.32 0.47 0.45 0.57	8 weeks ^r -0.44 -0.49 0.37 0.11 0.05 0.06 0.50 0.32 0.07		

Abbreviations: AAQ-II, Acceptance and Action Questionnaire; BDI, Beck Depression Inventory; BFI, Brief Fatigue Inventory; BIS, Body Image Scale; BPI, Brief Pain Inventory; BRS, Brief Resilience Scale; BSI-18, Brief Symptom Inventory; BPI-severity, Brief Pain Inventory – Pain Severity Subscale; CAMM, Child and Adolescent Mindfulness Measure; CAMS-R, Cognitive and Affective Mindfulness Scale—Revised; CARS, Concerns About Recurrence Scale; CESD, Center for Epidemiologic Studies Depression; CIS-FS, Checklist Individual Strength—Fatigue Severity; CSOSI, Calgary Symptoms of Stress Inventory; DAS, Dyadic Adjustment Scale; ECog, Everyday Cognition; ERQ, Emotion Regulation Questionnaire; ES, effect size/s; F, female; FACIT(-FS; -SP), Functional Assessment of Chronic Illness Therapy (—Fatigue Scale; —Spirituality); FACT(-B; -C; -G; -P; -O) Functional Assessment of Cancer Therapy (—Breast; —Colorectal; —General; —Prostate; —Ovarian); FCRI, Fear of Cancer Recurrence Inventory; FMI, Freiburg Mindfulness Inventory; FFMQ (-SF), Five Facets of Mindfulness Questionnaire (—Short Form); FOP-Q-SF, Fear Of Progression Questionnaire—Short Form; FSDS, Female Sexual Distress Scale; FSFI, Female Sexual Function Index, FSI, Fatigue Symptom Inventory; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; IIEF, International Index of Erectile Function; IMS, Interpersonal Mindfulness Scale; ISI, Insomnia Severity Index; Ma, male; MAAS, Mindful Attention Awareness Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; MDASI, MD Anderson Symptom Inventory; MHC-SF, Mental Health Continuum—Short Form M, mean; Mdn, median; mo, month/s; MPN-SAF, MPN Symptom Assessment Form; N/A, data not available; PANAS, Positive and Negative Affect Schedule; PCQL-32-Pf, Pediatric Cancer Quality of Life Inventory 32-Psychological Functioning subscale; PDI, Pain Disability Index; PSQI, Pittsburgh Sleep Quality Index; PROMIS, Patient—Reported Outcomes Measurement Information System; PSWQ-A, Penn State Worry Questionnaire—Abbreviated; PSS, T

Social Support, Friends; POMS, Profile of Mood States PTGI, Posttraumatic Growth Inventory; QoL, quality of life; QMI, Quality of Marriage Index; R, recommendation; RRQ, Rumination and Reflection Questionnaire; SCS, Self-Compassion Scale; SF-12/SF-36, Short Form Health Survey; SPS, Social Provisions Scale; STAI-S, State scale of State Trait Anxiety Inventory; VAL-sum, Bull's Eye Values Inventory – Summary score; we, weeks; WHO-5, World Health Organisation 5-item well-being index;

- a primary outcomes are initialized
- ^b baseline to postintervention assessment data (duration is reported above the effect sizes)
- ^c baseline to follow up assessment data (duration is reported above the effect sizes)
- ^d data of unpaired patients only not applicable
- e unclear what proportion of participants were adherent to what proportion of recommended practice
- f practice frequency/duration recommendation is unclear
- g unclear how many participants were not reported
- h unclear if of those who were enrolled or who completed the intervention
- i only the results of Calm app are reported as it was superior to 10% Happier app in terms of feasibility and authors recommend it for future trials
- ^j results of participants who used *Calm* app (29) during the first 4 weeks of the study (before having used another app or received education) compared to those who received an education control (51) also during the first 4 weeks
- k postintervention to follow-up assessment data
- ¹ in this case, authors reported effect size as Hedge's g_{av}
- m results of assessed psychosocial outcomes was not reported
- ⁿ results of mindfulness group compared to usual care group are reported here
- ° data of sample expanded by waitlist group which completed the intervention afterward
- ^p only the results of individual Mindfulness-based intervention are reported
- ^r data of original intervention sample (not of expanded by waitlist group which completed the intervention afterward)

Table 4. Risk of bias assessment

Study	Selection bias		Performance and detection bias		Attrition bias	Reporting bias	Other biases		
	1. Random sequence generation	2. Allocation concealment	3. Blinding of participants and personnel	4. Blinding of outcome assessment	5. Complete outcome data or intention-to- treat analysis used	6. All outcomes reported	7. Similar groups	8. Presence of control group	
Atreya et al. (2018) [75]	_	_	_	_	No	No	_	No	
Brotto et al. (2016) [76]	_	_	_	_	No	No	_	No	
Bruggeman-Everts et al. (2017) [84]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Bruggeman-Everts et al. (2015) [77]	_	_	_	_	Yes	Yes	_	No	
Campo et al. (2017) [78]	_	_	_	_	No	Yes	_	No	
Compen et al. (2018) [62]; Cillessen et al. (2018) [70]; Bisseling et al. (2019) [73]	Yes	Yes	No	No	Yes	No	Yes	Yes	
Donovan et al. (2019) [79]	_	_	_	_	Yes	Yes	_	No	
Hawkes et al. (2014) [71]; Hawkes et al. (2013) [74]	Yes	Yes	No	No	No	Yes	Yes	Yes	
Huberty et al. (2019) [85]; Puzia et al. (2020) [72]	Unclear	Unclear	No	No	No	Yes	Yes	Yes	
Chambers et al. (2017) [86]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Kinner et al. (2018) [80]	_	_	_	_	No	Yes	_	No	
Kubo et al. (2019) [87]	Yes	Yes	No	No	Yes	Yes	Unclear	Yes	

Study	Selection bias		Performance and dete	ction bias	Attrition bias	Reporting bias	Other biases		
	1. Random sequence generation	2. Allocation concealment	3. Blinding of participants and personnel	4. Blinding of outcome assessment	5. Complete outcome data or intention-to- treat analysis used	6. All outcomes reported	7. Similar groups	8. Presence of control group	
Kubo et al. (2018) [54]	_	_	_	_	No	Yes	_	No	
Lengacher et al. (2018) [81]	_	_	_	_	Yes	Yes	_	No	
Messer et al. (2019) [88]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Mikolasek et al. (2018) [82]	_	_	_	_	No	No	_	No	
Milbury et al. (2019) [89]	Yes	Yes	No	No	Yes	Yes	Unclear	Yes	
Mosher et al. (2018) [90]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Nissen et al. (2020) [91]	Yes	Yes	No	No	Yes	No	Yes	Yes	
Plumb Vilardaga et al. (2020) [83]	_	_	_	_	Yes	Yes	Yes	No	
Price-Blackshear et al. (2020) [92]	Unclear	Unclear	No	No	No	Yes	Yes	Yes	
Rosen et al. (2018) [93]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Russell et al. (2019) [94]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	
Zernicke et al. (2014) [95]; Zernicke et al. (2016) [97]	Yes	Yes	No	No	Yes	Yes	Yes	Yes	